Our data, in combination with findings of favorable lipid profiles and reduced risk of coronary artery disease5,6,8, provide human genetics support for ANGPTL4 inhibition as a therapeutic strategy for prevention and possibly treatment of metabolic disease. The gene discussed is ANGPTL4; the disease is metabolic disease.